Related Experiment Video
Updated: Jul 12, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Systemic lupus erythematosus: Phase 2 trials to watch in 2026
Eric F Morand1, Sarah A Jones2
1Centre for Inflammatory Disease, Monash University, Clayton, VIC, Australia; Rheumatology, Monash Health, Clayton, VIC, Australia.
Med (New York, N.Y.)
|July 10, 2026
Summary
Clinical trials for systemic lupus erythematosus (SLE) are advancing in 2026. New trials focus on novel mechanisms, offering insights into SLE pathogenesis.
Area of Science:
- Rheumatology
- Immunology
- Clinical Research
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
- Current treatments aim to manage symptoms and reduce disease activity.
- Understanding SLE pathogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To provide an overview of ongoing clinical trials for SLE in 2026.
- To highlight trials investigating novel therapeutic mechanisms.
- To discuss the potential insights these trials may offer into SLE pathogenesis.
Main Methods:
- Review of ongoing clinical trials for SLE.
- Identification of trials targeting novel disease mechanisms.
- Categorization of trials based on therapeutic targets and disease stage.
Main Results:
- A significant number of SLE clinical trials are active in 2026.
- Several trials are exploring innovative therapeutic targets beyond established pathways.
- These novel trials represent a shift towards precision medicine in SLE treatment.
Conclusions:
- The landscape of SLE clinical trials is dynamic and expanding.
- Novel mechanistic trials hold promise for deeper understanding and improved SLE management.
- Continued research is essential to translate these findings into clinical practice.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...